Benitec Biopharma Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' equity - Additional information (Detail)

Stockholders' equity - Additional information (Detail) $ / shares in Units, $ in Millions									3 Months Ended	6 Months Ended
	Nov. 24, 2023 $ / shares shares	Oct. 17, 2023 $ / shares shares	Aug. 11, 2023 USD ($) $ / shares shares	Oct. 27, 2022 $ / shares shares	Oct. 17, 2022 shares	Sep. 15, 2022 $ / shares shares	Dec. 09, 2020	Apr. 22, 2020 shares	Sep. 30, 2023 shares	Dec. 31, 2023 USD ($) shares	Jun. 30, 2023 shares	Dec. 07, 2022 shares	Dec. 08, 2021 shares	Dec. 06, 2019 shares $ / shares
Sale of stock issue price per share \| $ / shares			$ 1.9299
Class of warrant or right, exercise price of warrants or rights \| $ / shares						$ 11.22
Net proceeds from public offering \| $			$ 27.9
Unrecognised share based compensation expense \| $										$ 0.5
Common Stock Shares Authorized										160,000,000	160,000,000
Warrants outstanding									33,476,440	33,431,440	2,348,039
Two Thousand And Twenty Equity Incentive Plan [Member]
Common stock shares reserved for future issuance													1,204,537
Two Thousand And Twenty Equity Incentive Plan [Member] \| Employee stock option [Member]
Share based compensation by share based award unrecognized expense remaining period of recognition										2 years 7 months 6 days
Share based compensation by share based award contractual term							10 years
Maximum [Member]
Common Stock Shares Authorized												160,000,000	40,000,000
Minimum [Member]
Common Stock Shares Authorized												40,000,000	10,000,000
Common Stock [Member]
Warrants convertible into shares of common stock on exercise			2,331,606					6,300		458,134
Cashless exercise of purchase warrants (In shares)								2,201
Common Warrants [Member]
Class of warrant or right, exercise price of warrants or rights \| $ / shares			$ 3.86
Warrants convertible into shares of common stock on exercise			2,331,606							458,134
Purchase warrants [Member]
Class of warrant or right, exercise price of warrants or rights \| $ / shares														$ 178.5
Warrants convertible into shares of common stock on exercise														12,600
Number of series of warrants issued														4
Expiry date of warrants														Dec. 06, 2024
Series 2 Warrants [Member]
Class of warrant or right, exercise price of warrants or rights \| $ / shares	$ 1.93
Class Of Warrants Or Rights Excercised During The Period	20,000
Pre-funded warrants [Member]
Sale of stock issue price per share \| $ / shares			$ 1.9298
Class of warrant or right, exercise price of warrants or rights \| $ / shares		$ 0.0001	$ 0.0001
Class Of Warrants Or Rights Excercised During The Period		25,000		9,804	117,939
IPO [Member]
Sale of stock number of shares issued in the transaction			875,949			1,037,520
Sale of stock issue price per share \| $ / shares			$ 1.9299			$ 10.03
Warrants convertible into shares of common stock on exercise			16,002,175
Class of warrant or rights issued during period			16,002,175
Issue of common stock and warrant price per share			1.93%			10.20%
Class of warrants or rights issue price per unit \| $ / shares			$ 0.0001			$ 0.17
IPO [Member] \| Series 2 Warrants [Member]
Class of warrant or right, exercise price of warrants or rights \| $ / shares			$ 1.9299
Warrants convertible into shares of common stock on exercise						1,753,503
Warrants outstanding						29,809,471
IPO [Member] \| Pre-funded warrants [Member]
Class of warrant or right, exercise price of warrants or rights \| $ / shares						$ 0.0017
Warrants convertible into shares of common stock on exercise			15,126,226			715,979
Class of warrant or rights issued during period			15,126,226			12,171,628
Pre-funded warrants [Member]
Sale of stock number of shares issued in the transaction			15,126,226						15,126,226
Class of warrant or right, exercise price of warrants or rights \| $ / shares				$ 0.0017